Spots Global Cancer Trial Database for checkpoint inhibitors
Every month we try and update this database with for checkpoint inhibitors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cancer Patients Treated With Immunotherapy in Intensive Care Unit | NCT03357861 | Cancer Critical Illnes... Immunotherapy | 18 Years - | University Hospital, Grenoble | ||
| Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) | NCT02307149 | Melanoma | CAVATAK Ipilimumab | 18 Years - | Viralytics | |
| Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment | NCT03171064 | PD-1 Antibodies Exercise Melanoma | Resistance and ... | 18 Years - | University Hospital Heidelberg | |
| A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma | NCT05732805 | Melanoma Melanoma (Skin) Melanoma Stage ... Melanoma Stage ... Melanoma Unrese... Melanoma Metast... Melanoma Advanc... | BCD-217 BCD-100 Placebo | 18 Years - | Biocad | |
| Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer | NCT05467670 | Ovarian Cancer | Pembrolizumab ALX148 Doxorubicin | 18 Years - | University of Pittsburgh | |
| Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment | NCT03171064 | PD-1 Antibodies Exercise Melanoma | Resistance and ... | 18 Years - | University Hospital Heidelberg | |
| Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells | NCT03644498 | Cancer | Non-Interventio... | 18 Years - | Bristol-Myers Squibb | |
| Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) | NCT02307149 | Melanoma | CAVATAK Ipilimumab | 18 Years - | Viralytics | |
| Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04892043 | Adult Solid Tum... | SQZ-AAC-HPV Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma | NCT06240143 | Melanoma | Ipilimumab Nivolumab Nivolumab | 18 Years - | The Netherlands Cancer Institute | |
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer | NCT03288545 | Carcinoma, Tran... Urinary Bladder... Urologic Neopla... Renal Pelvis Ne... Urothelial Canc... Ureteral Neopla... Urethral Neopla... | enfortumab vedo... pembrolizumab cisplatin carboplatin gemcitabine | 18 Years - | Astellas Pharma Inc | |
| Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors | NCT03454243 | Advanced or Met... | RXDX-106 | 18 Years - | Hoffmann-La Roche | |
| Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma | NCT06240143 | Melanoma | Ipilimumab Nivolumab Nivolumab | 18 Years - | The Netherlands Cancer Institute | |
| Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04892043 | Adult Solid Tum... | SQZ-AAC-HPV Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma | NCT05751928 | Melanoma Stage ... Melanoma (Skin) | BCD-217 anti-PD1 Excision of the... Regional lympha... | 18 Years - | Biocad | |
| Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT04084951 | Adult Solid Tum... | SQZ-PBMC-HPV Atezolizumab Ipilimumab Nivolumab | 18 Years - | SQZ Biotechnologies | |
| A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma | NCT05751928 | Melanoma Stage ... Melanoma (Skin) | BCD-217 anti-PD1 Excision of the... Regional lympha... | 18 Years - | Biocad | |
| A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy | NCT04571398 | Cancer | ApricityRx mobi... | 18 Years - | Apricity Health, LLC | |
| Patient-Reported AutoImmunity Secondary to Cancer immunothErapy | NCT03849131 | Opportunistic A... | Biological coll... | 18 Years - | University Hospital, Strasbourg, France | |
| A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma | NCT05732805 | Melanoma Melanoma (Skin) Melanoma Stage ... Melanoma Stage ... Melanoma Unrese... Melanoma Metast... Melanoma Advanc... | BCD-217 BCD-100 Placebo | 18 Years - | Biocad | |
| Cancer Patients Treated With Immunotherapy in Intensive Care Unit | NCT03357861 | Cancer Critical Illnes... Immunotherapy | 18 Years - | University Hospital, Grenoble | ||
| Treatment With Immunological Checkpoint Inhibitors of HIV-infected Subjects With Cancer | NCT03767465 | HIV Infection Cancer | - | IrsiCaixa | ||
| Defining the Role of the Skin Microbiome in Immune-related Adverse Events | NCT04734704 | Vitiligo Skin Melanoma | skin swabs at l... skin swabs on s... | 18 Years - | University Hospital, Bordeaux | |
| Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors | NCT03454243 | Advanced or Met... | RXDX-106 | 18 Years - | Hoffmann-La Roche | |
| Defining the Role of the Skin Microbiome in Immune-related Adverse Events | NCT04734704 | Vitiligo Skin Melanoma | skin swabs at l... skin swabs on s... | 18 Years - | University Hospital, Bordeaux | |
| Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma | NCT05689671 | Non-Small Cell ... | Atezolizumab Nab paclitaxel Carboplatin Pembrolizumab Cisplatin Carboplatin Pemetrexed | 18 Years - | Charite University, Berlin, Germany | |
| Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors | NCT05357898 | Adult Solid Tum... | SQZ-eAPC-HPV Pembrolizumab | 18 Years - | SQZ Biotechnologies | |
| Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer | NCT03951415 | Endometrial Neo... Uterine Neoplas... Endometrium Can... | PARP inhibitor ... | 18 Years - | Leiden University Medical Center | |
| Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer | NCT05467670 | Ovarian Cancer | Pembrolizumab ALX148 Doxorubicin | 18 Years - | University of Pittsburgh |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
